Advancing More Personalised & Efficacious Therapies to Transform the Standard of Care in the Evolving Rare, Genetic, & Common Kidney Disease Landscape
As CKD treatment options expand, the challenge for kidney drug developers is becoming increasingly precise: identifying the right mechanism for the right patient, selecting endpoints that can demonstrate meaningful benefit, and differentiating new therapies against an increasingly effective standard of care.
The 9th CKD Summit brings discovery, translational, clinical, regulatory and medical leaders into one room to tackle that next phase. Across common, rare and genetic kidney disease, the program goes beyond broad CKD labels to examine disease biology, patient stratification, kidney-targeted delivery, new biomarkers and endpoints, evolving trial design and the practical sequencing of an expanding treatment landscape.
Join the teams actively building the next generation of renal medicines to compare approaches, pressure-test development decisions and identify where the strongest opportunities now sit across CKD.
-
The CKD Summit assembles a great panel and attendees from both academia and industry in a setting that fosters 1:1 interactions and deep discussion into science and how best to advance projects. The vendors who also attend provide great value and new ideas for projects/technologies.
Shawn Badal, Director, Kidney Discovery Research, Eli Lilly
-
The CKD Summit brings together experienced professionals and thought leaders in chronic kidney disease to share high-impact insights and cutting-edge developments. With a strong focus on CKD, the Summit offers exceptional opportunities for scientific exchange, strategic collaboration, and meaningful networking across the kidney health community.
Jennifer McKenzie, Senior Clinical Program Leader in CRM, Boehringer Ingelheim
-
The conference is a great opportunity to connect and learn from peers and experts in CKD and to share and advance our knowledge in the pursuit of better treatments.
Ginny Collins, Senior Director, Regulatory Affairs, Apellis Pharmaceuticals
Explore the Full Event Guide
- See the full 3-day journey from rare & genetic disease strategy through discovery, clinical development and implementation
- Meet the 35+ confirmed speakers shaping current CKD R&D decisions
- Preview data-led case studies spanning IgAN, FSGS, PKD, fibrosis, AAV, RNA delivery and precision nephrology
- Compare the three interactive workshops on CKD models, trial design and next-generation endpoints
- Share one concise source of agenda, faculty and networking information with your wider renal team
Official 2026 Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Follow the decisions shaping renal R&D, from target validation and kidney-specific delivery to proof-of-concept, endpoints and treatment strategy.
Partner With Us
Put your renal expertise in front of teams actively seeking better models, biomarkers, patient-finding tools and clinical development support.
Join the CKD Community
Build relationships across discovery, translational, clinical, regulatory and medical teams working on common, rare and genetic kidney disease.